スロデキシド
- 関
- vessel
WordNet
- a craft designed for water transportation (同)watercraft
- an object used as a container (especially for liquids)
- a tube in which a body fluid circulates (同)vas
PrepTutorEJDIC
- (比較的大型の)『船』 / (特に液体を入れる)容器,器 / (動植物の)『管』,導管,脈管
Wikipedia preview
出典(authority):フリー百科事典『ウィキペディア(Wikipedia)』「2015/05/30 19:56:19」(JST)
[Wiki en表示]
Sulodexide
Systematic (IUPAC) name |
Glucurono-2-amino-2-deoxyglucoglucan sulfate |
Clinical data |
AHFS/Drugs.com |
International Drug Names |
Routes of
administration
|
Oral, Subcutaneous, Intravenous, Intramuscular |
Identifiers |
CAS Registry Number
|
57821-29-1 Y |
ATC code
|
B01AB11 |
DrugBank |
DB06271 Y |
KEGG |
D08547 Y |
Chemical data |
Y (what is this?) (verify) |
Sulodexide is a highly purified mixture of glycosaminoglycans composed of low molecular weight heparin (80%) and dermatan sulfate (20%).
Contents
- 1 Pharmacology
- 2 Uses
- 3 References
- 4 External links
Pharmacology
The low molecular weight of both sulodexide fractions allows for extensive oral absorption compared to unfractionated heparin. The pharmacological effects of sulodexide differ substantially from other glycosaminoglycans and are mainly characterized by a prolonged half-life and reduced effect on global coagulation and bleeding parameters.[1] Due to the presence of both glycosaminoglycan fractions, sulodexide potentiates the antiprotease activities of both antithrombin III and heparin cofactor II simultaneously.[2]
Uses
Clinically, sulodexide is used for the prophylaxis and treatment of thromboembolic diseases however recent research has also demonstrated the beneficial effects of sulodexide in animal models of reperfusion injury[3] and the treatment of diabetic nephropathy.[4][5][6] In combination with Melatonin, Sulodexide have been shown to be a viable treatment option for patients suffering from central or sensorineural tinnitus.[7][8]
References
- ^ Lauver DA, Lucchesi BR (2006). "Sulodexide: a renewed interest in this glycosaminoglycan". Cardio drug rev 24 (3-4): 214–26. doi:10.1111/j.1527-3466.2006.00214.x. PMID 17214598.
- ^ Harenberg J (1998). "Review of pharmacodynamics, pharmacokinetics, and therapeutic properties of sulodexide". Med Res Rev 18 (1): 1–20. doi:10.1002/(SICI)1098-1128(199801)18:1<1::AID-MED1>3.0.CO;2-4. PMID 9436179.
- ^ Lauver DA, Booth EA, White AJ, Poradosu E, Lucchesi BR (2005). "Sulodexide attenuates myocardial ischemia/reperfusion injury and the deposition of C-reactive protein in areas of infarction without affecting hemostasis". J Pharmacol Exp Ther 312 (2): 794–800. doi:10.1124/jpet.104.075283. PMID 15365091.
- ^ Achour A, Kacem M, Dibej K, Skhiri H, Bouraoui S, El May M. (2005). "One year course of oral sulodexide in the management of diabetic nephropathy". J Nephrol 18 (5): 568–574. PMID 16299683.
- ^ Gambaro G, Venturini AP, Noonan DM et al. (1994). "Treatment with a glycosaminoglycan formulation ameliorates experimental diabetic nephropathy". Kidney Int 46 (3): 797–806. doi:10.1038/ki.1994.335. PMID 7527876.
- ^ Škrhaa J, , J Perušičováb J et al. (1997). "Treatment with a glycosaminoglycan formulation ameliorates experimental diabetic nephropathy". Diabetes Res Clin Practice 38 (1): 25–31. doi:10.1016/S0168-8227(97)00076-4. PMID 9347243.
- ^ Neri G, Baffa C, De Stefano A et al. (2009). "Management of tinnitus: oral treatment with melatonin and sulodexide". J. Biol. Regul. Homeost. Agents 23 (2): 103–10. PMID 19589291.
- ^ Neri G. De Stefano A. Baffa C. Kulamarva G. Di Giovanni P. Petrucci G. Poliandri A. Dispenza F. Citraro L. Croce A. ,"Treatment of central and sensorineural tinnitus with orally administered Melatonin and Sulodexide: personal experience from a randomized controlled study." Acta Otorhinolaryngologica Italica. 29(2):86-91, 2009 Apr.
External links
- sulodexide at the US National Library of Medicine Medical Subject Headings (MeSH)
Antithrombotics (thrombolytics, anticoagulants and antiplatelet drugs) (B01)
|
|
Antiplatelet drugs |
Glycoprotein IIb/IIIa inhibitors
|
- Abciximab
- Eptifibatide
- Tirofiban
- Roxifiban
- Orbofiban
|
|
ADP receptor/P2Y12 inhibitors
|
- Thienopyridines
- Clopidogrel
- Prasugrel
- Ticlopidine
- Nucleotide/nucleoside analogs
- Cangrelor
- Elinogrel
- Ticagrelor
|
|
Prostaglandin analogue (PGI2)
|
- Beraprost
- Iloprost
- Prostacyclin
- Treprostinil
|
|
COX inhibitors
|
- Acetylsalicylic acid/Aspirin#
- Aloxiprin
- Carbasalate calcium
- Indobufen
- Triflusal
|
|
Thromboxane inhibitors
|
- Thromboxane synthase inhibitors
- Dipyridamole (+Aspirin)
- Picotamide
- Receptor antagonists
|
|
Phosphodiesterase inhibitors
|
- Cilostazol
- Dipyridamole
- Triflusal
|
|
Other
|
- Cloricromen
- Ditazole
- Vorapaxar
|
|
|
Anticoagulants |
Vitamin K antagonists
(inhibit II, VII, IX, X)
|
- Coumarins: Acenocoumarol
- Coumatetralyl
- Dicoumarol
- Ethyl biscoumacetate
- Phenprocoumon
- Warfarin#
- 1,3-Indandiones: Clorindione
- Diphenadione
- Phenindione
- Other: Tioclomarol
|
|
Factor Xa inhibitors
(with some II inhibition)
|
Heparin group/
glycosaminoglycans/
(bind antithrombin)
|
- Low molecular weight heparin
- Bemiparin
- Certoparin
- Dalteparin
- Enoxaparin
- Nadroparin
- Parnaparin
- Reviparin
- Tinzaparin‡
- Oligosaccharides
- Fondaparinux
- Idraparinux§
- Heparinoids
- Danaparoid
- Dermatan sulfate
- Sulodexide
|
|
Direct Xa inhibitors
|
- Xabans
- Apixaban
- Betrixaban§
- Darexaban§
- Edoxaban
- Otamixaban§
- Rivaroxaban
|
|
|
Direct thrombin (IIa) inhibitors
|
- Bivalent: Hirudin
- Bivalirudin
- Desirudin
- Lepirudin
- Univalent: Argatroban
- Dabigatran
- Melagatran‡
- Ximelagatran‡
|
|
Other
|
- Antithrombin III
- Defibrotide
- Protein C
- Ramatroban
- REG1
|
|
|
Thrombolytic drugs/
fibrinolytics |
- Plasminogen activators: r-tPA
- Alteplase
- Reteplase
- Tenecteplase
- UPA
- Anistreplase
- Monteplase
- Streptokinase#
- Other serine endopeptidases: Ancrod
- Brinase
- Fibrinolysin
|
|
Non-medicinal |
|
|
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
Index of cells from bone marrow
|
|
Description |
- Immune system
- Cells
- Physiology
- coagulation
- proteins
- granule contents
- colony-stimulating
- heme and porphyrin
|
|
Disease |
- Red blood cell
- Monocyte and granulocyte
- Neoplasms and cancer
- Histiocytosis
- Symptoms and signs
- Blood tests
|
|
Treatment |
- Transfusion
- Drugs
- thrombosis
- bleeding
- other
|
|
|
UpToDate Contents
全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.
English Journal
- Degradation of the endothelial glycocalyx in clinical settings: searching for the sheddases.
- Becker BF1, Jacob M, Leipert S, Salmon AH, Chappell D.
- British journal of clinical pharmacology.Br J Clin Pharmacol.2015 Mar 16. doi: 10.1111/bcp.12629. [Epub ahead of print]
- The endothelial glycocalyx has a profound influence at the vascular wall on the transmission of shear stress, on the maintenance of a selective permeability barrier and a low hydraulic conductivity, and on attenuating firm adhesion of blood leukocytes and platelets. Major constituents of the glycoca
- PMID 25778676
- Clinical pharmacology of melatonin in the treatment of tinnitus: a review.
- Miroddi M1, Bruno R, Galletti F, Calapai F, Navarra M, Gangemi S, Calapai G.
- European journal of clinical pharmacology.Eur J Clin Pharmacol.2015 Mar;71(3):263-70. doi: 10.1007/s00228-015-1805-3. Epub 2015 Jan 20.
- PURPOSE: We performed a review with the purpose to summarise, analyse and discuss the evidence provided by clinical studies evaluating effectiveness of melatonin in the cure of tinnitus. Due to the fact that there is no satisfactory treatment for tinnitus, clinical research has explored new therapeu
- PMID 25597877
- Leg ulcer and osteomyelitis due to methicillin-susceptible Staphylococcus aureus infection after fracture repair treatment: a case highlighting the potential role of prostaglandin E1 vasodilator.
- Bentivegna E1, Citarrella E1, Vivaldi R1, De Luca D1, Maira GG1, Casuccio A1, Di Carlo P1.
- Le infezioni in medicina : rivista periodica di eziologia, epidemiologia, diagnostica, clinica e terapia delle patologie infettive.Infez Med.2015 Mar 1;23(1):69-73.
- Prostaglandins appear to reduce biofilm formation and chronicization of infections, and stimulate a rapid and effective clearance of infecting micro-organisms. We report a case of recovery from methicillin-susceptible Staphylococcus aureus (MSSA) osteomyelitis after multidisciplinary management with
- PMID 25819055
Japanese Journal
- Vascular dementia Italian sulodexide study (VA.D.I.S.S.). Clinical and biological results.
Related Links
- Pharmacology [edit] The low molecular weight of both sulodexide fractions allows for extensive oral absorption compared to unfractionated heparin. The pharmacological effects of sulodexide differ substantially from other ...
- 望まれた腎臓病の糖尿病の患者に寄与しなかった何が腎臓を保護する有望で新しい薬剤であるためにアメリカの社会の腎臓学 (JASN) のジャーナルの次の問題で現われる調査に従って。 結果は質問に薬剤の sulodexide の実用性を ...
Related Pictures
★リンクテーブル★
[★]
- 関
- angio、blood vessel、canal、chamber、conduit、container、duct、sulodexide、vas、vascular、vein